DPP4 inhibitors and cardiovascular outcomes

safety on heart failure

Chang Xia, Aditya Goud, Jason D’Souza, Chanukya H. Dahagam, Xiaoquan Rao, Sanjay Rajagopalan, Jixin Zhong

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Diabetes is an important risk factor for cardiovascular disease. However, clinical data suggests intensive glycemic control significantly increase rather than decrease cardiovascular mortality, which is largely due to the fact that a majority of oral anti-diabetic drugs have adverse cardiovascular effect. There are several large-scale clinical trials evaluating the cardiovascular safety of DPP4 inhibitors, a novel class of oral anti-diabetic medications, which have been recently completed. They were proven to be safe with regard to cardiovascular outcomes. However, concerns on the safety of heart failure have been raised as the SAVOR-TIMI 53 trial reported a 27% increase in the risk for heart failure hospitalization in diabetic patients treated with DPP4 inhibitor saxagliptin. In this review, we will discuss recent advances in the heart failure effects of DPP4 inhibition and GLP-1 agonism.

Original languageEnglish (US)
Pages (from-to)299-304
Number of pages6
JournalHeart Failure Reviews
Volume22
Issue number3
DOIs
StatePublished - May 1 2017
Externally publishedYes

Fingerprint

Heart Failure
Safety
Glucagon-Like Peptide 1
Hospitalization
Cardiovascular Diseases
Clinical Trials
Mortality
Pharmaceutical Preparations
saxagliptin

Keywords

  • Cardiovascular outcomes
  • DPP4
  • Heart failure
  • Incretin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Xia, C., Goud, A., D’Souza, J., Dahagam, C. H., Rao, X., Rajagopalan, S., & Zhong, J. (2017). DPP4 inhibitors and cardiovascular outcomes: safety on heart failure. Heart Failure Reviews, 22(3), 299-304. https://doi.org/10.1007/s10741-017-9617-4

DPP4 inhibitors and cardiovascular outcomes : safety on heart failure. / Xia, Chang; Goud, Aditya; D’Souza, Jason; Dahagam, Chanukya H.; Rao, Xiaoquan; Rajagopalan, Sanjay; Zhong, Jixin.

In: Heart Failure Reviews, Vol. 22, No. 3, 01.05.2017, p. 299-304.

Research output: Contribution to journalReview article

Xia, C, Goud, A, D’Souza, J, Dahagam, CH, Rao, X, Rajagopalan, S & Zhong, J 2017, 'DPP4 inhibitors and cardiovascular outcomes: safety on heart failure', Heart Failure Reviews, vol. 22, no. 3, pp. 299-304. https://doi.org/10.1007/s10741-017-9617-4
Xia, Chang ; Goud, Aditya ; D’Souza, Jason ; Dahagam, Chanukya H. ; Rao, Xiaoquan ; Rajagopalan, Sanjay ; Zhong, Jixin. / DPP4 inhibitors and cardiovascular outcomes : safety on heart failure. In: Heart Failure Reviews. 2017 ; Vol. 22, No. 3. pp. 299-304.
@article{f405385c5ff54de0915438e336db1fca,
title = "DPP4 inhibitors and cardiovascular outcomes: safety on heart failure",
abstract = "Diabetes is an important risk factor for cardiovascular disease. However, clinical data suggests intensive glycemic control significantly increase rather than decrease cardiovascular mortality, which is largely due to the fact that a majority of oral anti-diabetic drugs have adverse cardiovascular effect. There are several large-scale clinical trials evaluating the cardiovascular safety of DPP4 inhibitors, a novel class of oral anti-diabetic medications, which have been recently completed. They were proven to be safe with regard to cardiovascular outcomes. However, concerns on the safety of heart failure have been raised as the SAVOR-TIMI 53 trial reported a 27{\%} increase in the risk for heart failure hospitalization in diabetic patients treated with DPP4 inhibitor saxagliptin. In this review, we will discuss recent advances in the heart failure effects of DPP4 inhibition and GLP-1 agonism.",
keywords = "Cardiovascular outcomes, DPP4, Heart failure, Incretin",
author = "Chang Xia and Aditya Goud and Jason D’Souza and Dahagam, {Chanukya H.} and Xiaoquan Rao and Sanjay Rajagopalan and Jixin Zhong",
year = "2017",
month = "5",
day = "1",
doi = "10.1007/s10741-017-9617-4",
language = "English (US)",
volume = "22",
pages = "299--304",
journal = "Heart Failure Reviews",
issn = "1382-4147",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - DPP4 inhibitors and cardiovascular outcomes

T2 - safety on heart failure

AU - Xia, Chang

AU - Goud, Aditya

AU - D’Souza, Jason

AU - Dahagam, Chanukya H.

AU - Rao, Xiaoquan

AU - Rajagopalan, Sanjay

AU - Zhong, Jixin

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Diabetes is an important risk factor for cardiovascular disease. However, clinical data suggests intensive glycemic control significantly increase rather than decrease cardiovascular mortality, which is largely due to the fact that a majority of oral anti-diabetic drugs have adverse cardiovascular effect. There are several large-scale clinical trials evaluating the cardiovascular safety of DPP4 inhibitors, a novel class of oral anti-diabetic medications, which have been recently completed. They were proven to be safe with regard to cardiovascular outcomes. However, concerns on the safety of heart failure have been raised as the SAVOR-TIMI 53 trial reported a 27% increase in the risk for heart failure hospitalization in diabetic patients treated with DPP4 inhibitor saxagliptin. In this review, we will discuss recent advances in the heart failure effects of DPP4 inhibition and GLP-1 agonism.

AB - Diabetes is an important risk factor for cardiovascular disease. However, clinical data suggests intensive glycemic control significantly increase rather than decrease cardiovascular mortality, which is largely due to the fact that a majority of oral anti-diabetic drugs have adverse cardiovascular effect. There are several large-scale clinical trials evaluating the cardiovascular safety of DPP4 inhibitors, a novel class of oral anti-diabetic medications, which have been recently completed. They were proven to be safe with regard to cardiovascular outcomes. However, concerns on the safety of heart failure have been raised as the SAVOR-TIMI 53 trial reported a 27% increase in the risk for heart failure hospitalization in diabetic patients treated with DPP4 inhibitor saxagliptin. In this review, we will discuss recent advances in the heart failure effects of DPP4 inhibition and GLP-1 agonism.

KW - Cardiovascular outcomes

KW - DPP4

KW - Heart failure

KW - Incretin

UR - http://www.scopus.com/inward/record.url?scp=85017517115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017517115&partnerID=8YFLogxK

U2 - 10.1007/s10741-017-9617-4

DO - 10.1007/s10741-017-9617-4

M3 - Review article

VL - 22

SP - 299

EP - 304

JO - Heart Failure Reviews

JF - Heart Failure Reviews

SN - 1382-4147

IS - 3

ER -